市场调查报告书
商品编码
1471950
近距离放射治疗设备市场规模和预测、全球和区域份额、趋势和成长机会分析报告范围:按产品类型、类型、应用、最终用户和地理位置Brachytherapy Devices Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type, Type, Application, End User, and Geography |
近距离治疗设备市场预测可以帮助该市场的利害关係人规划其成长策略。该市场预计将从2022年的3.1096亿美元成长到2030年的5.0175亿美元;预计 2022 年至 2030 年复合年增长率为 6.2%。
近距离放射治疗是一种用于治疗癌症的放射治疗形式。它涉及将放射性材料放入患者体内,以向受影响的区域提供高剂量的辐射。有两种类型的近距离放射治疗技术 - 低剂量率 (LDR) 和高剂量率 (HDR),这两种技术通常用于治疗前列腺癌。全球癌症盛行率的不断上升预计将促进近距离放射治疗的采用。此外,近距离放射治疗相对于传统治疗方法的优势,例如更短的治疗时间、更高的有效性以及近距离放射治疗设备的进步,可能会推动全球近距离放射治疗设备市场的成长。
影响近距离放射治疗设备市场的因素
近十年来,近距离放射治疗取得了重大进展,这要归功于治疗器、影像、治疗计划和临床试验的改进。此外,目前近距离放射治疗技术的研究不断改变这种治疗方式的实施方式。将近距离放射治疗与其他治疗方法(例如外部放射治疗、化疗、免疫治疗或手术)相结合已成为癌症治疗的一个有前景的趋势。例如,2021年8月《当代近距离放射治疗杂誌》发表的一篇文章中,开展了癌症联合治疗、肿瘤致敏和正常组织保护、分子放射生物学以及近距离放射治疗临床研究等方面的研究。结论是,近距离放射治疗与免疫治疗相结合可以改善局部肿瘤控制并增强未照射病灶的反应。
因此,近距离放射治疗设备和治疗的此类进步预计将在预测期内推动市场发展。
基于细分市场份额的近距离放射治疗设备市场分析:
近距离放射治疗设备市场依产品类型分为种子、近距离放射治疗后装机和施药器以及电子近距离放射治疗。近距离放射治疗后装置和给药器细分市场在 2022 年占据最大的市场份额,预计 2022 年至 2030 年复合年增长率最高。
市场根据类型分为高剂量率近距离治疗植入物和低剂量率近距离治疗植入物。低剂量率近距离放射治疗植入物细分市场将在 2022 年占据更大的近距离放射治疗设备市场份额,预计 2022 年至 2030 年将以更快的复合年增长率成长。
近距离治疗设备市场依应用分为乳癌、子宫颈癌、摄护腺癌、肺癌等。前列腺癌细分市场在 2022 年占据最大市场份额,预计 2022-2030 年复合年增长率最高。
就最终用户而言,市场分为医院和专科诊所、门诊手术中心等。到 2022 年,医院细分市场占据最大的市场份额。
区域近距离放射治疗设备市场分析:
从地理上看,全球近距离治疗设备市场分为北美、亚太地区、欧洲、中东和非洲以及南美洲和中美洲。从收入来看,2022年北美在近距离治疗设备市场份额中占据主导地位。这可归因于该地区女性乳癌和男性前列腺癌病例不断增加等因素。根据泛美卫生组织 (PAHO) 统计,2020 年,美洲估计有 400 万人被诊断出罹患癌症,预计到 2040 年这一数字将增加约 60%。
此外,BD、Isoray Inc. 和 Elekta 等市场参与者的存在以及先进近距离放射治疗设备的可用性为市场扩张提供了巨大的机会。例如,2021 年 7 月,GenesisCare 透过从 Elekta 采购 27 套 Flexitron 近距离治疗后装系统和服务协议,扩大了近距离治疗服务。这些先进的癌症治疗设备使 GenesisCare 能够跟上最新技术,并为其位于美国的中心的患者提供高品质的护理。
註 - 将为以下提到的地区/国家提供类似的分析
The brachytherapy devices market forecast can help stakeholders in this marketplace plan their growth strategies. The market is projected to grow from US$ 310.96 million in 2022 to US$ 501.75 million by 2030; it is projected to register a CAGR of 6.2% during 2022-2030.
Brachytherapy is a form of radiation treatment used to treat cancer. It involves placing radioactive materials inside the patient's body to deliver high doses of radiation to the affected areas. There are two types of brachytherapy techniques available - Low Dose Rate (LDR) and High Dose Rate (HDR), both of which are commonly used to treat prostate cancer. The increasing prevalence of cancer worldwide is expected to boost the adoption of brachytherapy treatment. Additionally, the advantages of brachytherapy over traditional treatment methods, such as shorter treatment times, greater effectiveness, and advancement in brachytherapy devices, are likely to drive growth in the global brachytherapy devices market.
Factors Affecting Brachytherapy Therapy Devices Market
Brachytherapy has undergone significant advancements in the last decade, attributed to improved applicators, imaging, treatment planning, and clinical trials. Moreover, the current research on brachytherapy technology continuously changes how this treatment modality is delivered. Combining brachytherapy with other treatments, such as external radiation therapy, chemotherapy, immunotherapy, or surgery, has become a promising trend in cancer management. For instance, in an article published by the Journal of Contemporary Brachytherapy in August 2021, studies on cancer treatment through combined modality, tumor sensitization and normal tissue protection, molecular radiation biology, and clinical investigations of brachytherapy were conducted. It was concluded that combining brachytherapy with immunotherapy can improve local tumor control and enhance non-irradiated lesion responses.
Therefore, such advancements in brachytherapy devices and treatments are anticipated to fuel the market during the forecast period.
Brachytherapy Therapy Devices Market Analysis Based on the Segmental Share:
The brachytherapy therapy devices market, by product type, is segmented into seeds, brachytherapy afterloaders and applicators, and electronic brachytherapy. The brachytherapy afterloaders and applicators segment held the largest market share in 2022 and is anticipated to register the highest CAGR during 2022-2030.
The market is bifurcated based on type into high-dose rate brachytherapy implant and low-dose rate brachytherapy implant. The low-dose rate brachytherapy implant segment held a larger brachytherapy devices market share in 2022 and is anticipated to grow at a faster CAGR from 2022 to 2030.
The brachytherapy devices market, by application, is segmented into breast cancer, cervical cancer, prostate cancer, lung cancer, and others. The prostate cancer segment held the largest market share in 2022 and is anticipated to register the highest CAGR during 2022-2030.
In terms of end user, the market is segmented into hospitals and specialty clinics, ambulatory surgical centers, and others. The hospitals segment held the largest market share in 2022. This can be attributed to the availability of better facilities and skilled physicians in hospitals over other surgical centers to perform minimally invasive procedures.
Regional Brachytherapy Therapy Devices Market Analysis:
Geographically, the global brachytherapy devices market is segmented into North America, Asia Pacific, Europe, the Middle East & Africa, and South & Central America. In terms of revenue, North America dominated the brachytherapy devices market share in 2022. The brachytherapy devices market in this region is dominated by the US. This can be attributed to factors such as the increasing cases of breast cancer among women and prostate cancer among men in the region. According to the Pan America Health Organization (PAHO), in 2020, an estimated 4 million people in the Americas were diagnosed with cancer, which is predicted to increase by ~60% by 2040.
Additionally, the presence of market players, such as BD, Isoray Inc., and Elekta, and the availability of advanced brachytherapy devices present a sizable opportunity for market expansion. For instance, in July 2021, GenesisCare expanded its brachytherapy service by procuring 27 Flexitron brachytherapy afterloader systems and service agreements from Elekta. These advanced cancer treatment devices enabled GenesisCare to keep up with the latest technology and provide high-quality care to its patients across their centers in the US.
Note - Similar analysis would be provided for below mentioned regions/countries
Note - Similar information would be provided for below list of companies